Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.

Cancer research communications - 1 Apr 2025

Liu Dazhi, Jee Justin, Drilon Alexander, Heilmann Andreas M, Allen Justin M, Schrock Alexa B, Keller-Evans Rachel B, Li Bob T

Abstract excerpt

ABSTRACT: Although ERBB2 (HER2) is an established oncogenic driver and therapeutic biomarker in several cancers, current drug approvals do not reflect the diverse spectrum of activating alterations across indications in which HER2-targeted therapies may yield clinical benefit. In most cancer types, HER2 status is defined by HER2 overexpression/amplification assessed by IHC and FISH, which do not provide genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ERBB2 gene

Share to ERBB3 gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Receptor, ErbB-3

Source

Open in PubMed Open full text

Identifiers

PMID: 40178042
DOI: 10.1158/2767-9764.CRC-24-0620
PMCID: PMC12022956

Genes

ERBB2
ERBB3
IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.PMID 40178042Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

HER2 alterations across solid tumors: implications for comprehensive testingSemantic proximity Read ↗

Genomic alterations of ERBB receptors in cancer: clinical implicationsSemantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.Semantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid CancersSemantic proximity Read ↗

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.Semantic proximity Read ↗

High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.Semantic proximity Read ↗

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

HER2 aberrations in cancer: implications for therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.